Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes of non-small cell lung cancer patients and have increased the possibility of long-term survival. However, few patients benefit from ICIs, and no predictive biomarkers other than tumor programmed cell death ligand 1 (PD-L1) e...
Main Authors: | Ryota Ushio, Shuji Murakami, Haruhiro Saito |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/7/1855 |
Similar Items
-
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
by: Hiroaki Kanemura, MD, MPH, et al.
Published: (2022-08-01) -
The Landscape of Immunotherapy for Retroperitoneal Sarcoma
by: Alicia A. Gingrich, et al.
Published: (2023-02-01) -
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
by: Paraskevi Vryza, et al.
Published: (2023-12-01) -
Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer
by: Kaitang Huang, et al.
Published: (2021-05-01) -
Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity
by: Zachary L. Z. Hay, et al.
Published: (2022-02-01)